- Division of Translational and Clinical Sciences – DTCS
- Review Branch:
- Cancer Therapeutics – CTH
- Study Section:
- Mechanisms of Cancer Therapeutics - 1 – MCT1
Dr. Dolores Arjona earned her Ph.D. in molecular biology and biochemistry at the Universidad Autonoma of Madrid in Spain. She subsequently completed her postdoctoral training at Virginia Commonwealth University and the Neuro-Oncology Branch at NCI. Her main research efforts were focused on molecular genetics and epigenetics of astrocytic gliomas and brain tumor stem cells. Prior to joining CSR, Dr. Arjona worked in the clinical genetic testing industry at GeneDx for over ten years. As director of the analysis department there, she provided administrative and technical oversight for the day-to-day operations of a large interdisciplinary and multicultural team, coordinating clinical and scientific expertise in assessing pathogenicity for sequence and copy number variations.